Sex hormone therapy encompasses estrogen, progesterone, and androgen preparations used for contraception, hormone replacement, and treatment of hormone-sensitive conditions. These medications modulate reproductive and metabolic processes through binding to nuclear steroid hormone receptors. Their use spans gynecology, endocrinology, oncology, and transgender medicine, requiring careful consideration of individual risks and benefits.
What Is Sex Hormone Therapy?
Sex hormone therapy includes a wide range of synthetic and bioidentical hormones used to supplement, replace, or antagonize endogenous sex steroids. Indications include contraception, menopausal hormone therapy, gender-affirming hormone therapy, treatment of hormone-sensitive cancers, and management of conditions such as endometriosis, uterine fibroids, and hypogonadism. The choice of agent, dose, and route is individualized based on treatment goals and contraindications.
Drug Classes and Mechanisms
Combined oral contraceptives contain an estrogen (ethinyl estradiol) and a progestin, suppressing ovulation through inhibition of gonadotropin release. Progestin-only contraceptives thicken cervical mucus and alter endometrial receptivity. Hormone replacement therapy (HRT) uses estrogen with or without progesterone for menopausal symptom management; progesterone is added in women with an intact uterus to prevent endometrial hyperplasia. Selective estrogen receptor modulators (SERMs) include tamoxifen (estrogen receptor antagonist in breast tissue, agonist in bone and endometrium) and raloxifene (antagonist in breast and endometrium, agonist in bone). Aromatase inhibitors (anastrozole, letrozole, exemestane) inhibit the conversion of androgens to estrogens, reducing circulating estrogen levels in postmenopausal women with hormone receptor-positive breast cancer. Androgens include testosterone preparations (gel, patches, injections, buccal tablets) for male hypogonadism. Anti-androgens include spironolactone (androgen receptor antagonist and weak diuretic) and finasteride (5-alpha-reductase inhibitor blocking conversion of testosterone to dihydrotestosterone).
Therapeutic Uses
Combined oral contraceptives are used for contraception, menstrual regulation, acne, and dysmenorrhea. HRT is effective for vasomotor symptoms and prevention of urogenital atrophy in menopause. Tamoxifen is standard adjuvant therapy for hormone receptor-positive breast cancer, while raloxifene is used for osteoporosis prevention in postmenopausal women at high breast cancer risk. Aromatase inhibitors are first-line endocrine therapy for postmenopausal breast cancer. Testosterone replacement treats symptomatic hypogonadism. Finasteride is used for benign prostatic hyperplasia and androgenetic alopecia.
Adverse Effects
Combined oral contraceptives increase the risk of venous thromboembolism, particularly in smokers and those over age 35. HRT similarly carries thromboembolic risk and may increase breast cancer risk with prolonged combined therapy. Tamoxifen increases endometrial cancer risk and venous thromboembolism. Aromatase inhibitors cause arthralgia, osteoporosis, and fractures. Testosterone therapy may cause erythrocytosis, sleep apnea, and prostate stimulation. Finasteride can cause sexual dysfunction and, rarely, persistent post-finasteride syndrome. Spironolactone causes hyperkalemia, gynecomastia, and menstrual irregularities.
Key Clinical Considerations
Thromboembolic risk is a major consideration for estrogen-containing therapies and SERMs. The benefits of HRT generally outweigh risks when initiated within 10 years of menopause onset. Aromatase inhibitors require bone density monitoring. Testosterone therapy is contraindicated in men with untreated prostate cancer. SERM therapy requires careful endometrial monitoring. Cardiovascular risk assessment should guide prescribing decisions across all sex hormone therapies.
Conclusion
Sex hormone therapy encompasses a diverse array of medications with applications in contraception, menopause management, oncology, and hormone deficiency states. Individualized risk-benefit assessment, regular monitoring, and patient counseling on potential adverse effects are essential for safe and effective use. Ongoing research continues to refine the therapeutic index and indications for these widely prescribed agents.
